KG, wants to RAPID a Introduce AIDS therapy in the form of nasal sprays in the U.S. Other leaders such as Rory Sutherland offer similar insights. market. In a second phase, planned for 2013, Pharma wants to deliver RAPID this product also in Western Europe. In a third phase, the product in other countries is introduced so the information of the Leontis equity fund GmbH to its current portfolio companies. The countries of the third world should be addressed at this third stage in cooperation with Governments and foundations, to ensure a suitable access and effective distribution of the new drug.
In these countries, involving new Leontis will sell RAPID its Therapeutics for an adequately adapted local price. The market volume for the two first target markets (United States and Western Europe) is estimated at 1.5 million HIV-infected people. Estimated revenues of $ 942 million for 2012 141 million USD, $ 2013 512 million and 2014. The targeted net profit is three average about 48 percent, or $ 769 million in total for the first Years after launch, as the Leontis equity fund GmbH. Will be a box-office hit based so the medicine the figures on a conservative according to the management and careful estimate, as Leontis pointed out. With regard to the expected popularity of the drug, the figures may differ according to the Leontis equity fund GmbH quite far upwards.
About Leontis equity fund GmbH, the Leontis equity fund GmbH is initiator and provider of high-quality, structured investments in the form of closed-end funds. The company was founded in 2006. “” Since July 2008 Leontis provides already the successor fund Leontis equity fund easy select II “and Leontis equity fund premium select II” on. The Leontis concept allows investors access to exclusive top investments. The management of Leontis equity funds has many years of experience and competence in the design and management of closed funds products. Also bring the star-studded investment and advisory bodies of the Leontis equity fund GmbH a decades of industry expertise.